On December 15, 2023, under the guidance of the Qianwan New District, Ningbo city, and hosted by BioVillage, Hangzhou Bay Life Science Park, the 2nd China Ningbo Bio Industry Development Conference & the 3rd New Drug Development Entrepreneurship Roadshow was held in Qianwan New District, Ningbo. Biomissile Pharmaceuticals Co., Ltd. participated in this competition and stood out among nearly 50 roadshow companies, winning the third prize. The topic is "New drug development based on the proprietary rapid and high-throughput Fully Human Domain Antibody Screening and Optimization Technologies (UDABTM & UDAB-MTM)”.
The conference provided roadshows, expert guidance, and policy support for bio innovative enterprises to assist in project financing and implementation. The winners of the roadshow will have the chance to get Ningbo Government support in policy, services and investment, as well as the multiple benefits from BioVillage in Kanghui Park.
About Biomissile
Biomissile Pharmaceuticals Co., Ltd. is a clinical stage biotech company focusing on developing fully human domain antibody (UDABTM) and multi-specific antibody (UDAB-MTM) to fight a range of diseases with global unmet medical needs. We aim to become a premium innovative biopharmaceutical company based on our unique platform technologies, strong pipeline, and outstanding team. We have established five proprietary platforms for rapid antibody discovery and optimization, including the leading platforms for fully human domain antibody (UDABTM) and multi-specific antibody (UDAB-MTM), as well as the largest libraries of phage, yeast and mammalian cell display platforms. Relying on the strong platform technologies, the company has more than 10 innovative candidates under development in a short period of time, including several First-in-Class domain antibodies (VH) and multi-specific UDAB-MTM molecules to specifically activate immune cells in the tumor microenvironment (TME). So far, two leading projects are in clinical stage (in Phase I &II respectively) and the third one is in IND filing stage.
Biomissile has successfully assembled a global, seasoned leadership team in antibody discovery, manufacturing, clinical, registration and business development. The core team members are composed of experts with an average of more than 20 years’ experience in biological R&D and commercialization. The company has a state-of-the-art R&D lab in Shanghai, a future GMP facility in Suzhou, and a global regulatory & BD team in Boston, USA. We are committed to the disruptive innovation of biological drugs to benefit patients worldwide.
Link to the news in Chinese:
https://mp.weixin.qq.com/s/YKBZec6jJ_fbw8EQ73X5Yg
BD: bd@biomissile.com
HR: hr@biomissile.com
Website: www.biomissile.com